Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home
16 items matching your search terms.
Filter the results.
Item type














New items since



Sort by relevance · date (newest first) · alphabetically
Pignone - Eligibility for aspirin for primary prevention in men increases when cancer mortality benefit added
by William Shawn Davis (wishda) published Jun 04, 2013 last modified Jun 06, 2013 09:07 AM — filed under:
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
Located in News
The value of randomized clinical trials in radiation oncology clinical practice
by William Shawn Davis (wishda) published May 29, 2013 last modified Jun 10, 2013 03:20 PM — filed under:
Cancer patients, physicians and insurers want to be sure that whatever therapy is recommended and provided to patients is based on evidence, preferably results from randomized clinical trials. But are there enough clinical trials data to provide this level of confidence?
Located in News
UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy
by Megan Fazekas-King (fazekask) published May 28, 2013 last modified Jun 13, 2013 02:22 PM — filed under:
While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. Scientists are trying to find another way to target the gene by blocking signals from another protein downstream.
Located in News
UNC scientists identify possible KRAS downstream target for pancreatic cancer therapy
by William Shawn Davis (wishda) published May 28, 2013 last modified May 28, 2013 01:55 PM — filed under:
While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. Scientists are trying to find another way to target the gene by blocking signals from another protein downstream.
Located in Old top news stories
Charles Perou Receives 2013 Battle Cancer Research Award
by William Shawn Davis published May 24, 2013 last modified May 24, 2013 04:04 PM — filed under:
Charles Perou, PhD, the May Goldman Shaw Distinguished Professor of Molecular Oncology, has been honored with the 2013 Hyman L. Battle Distinguished Cancer Research Award in recognition of his accomplishments in cancer research. Dr. Perou is a member of UNC Lineberger Comprehensive Cancer Center.
Located in News
Lymphedema therapy provides relief for cancer patients
by Dianne Shaw published Mar 25, 2013 last modified Apr 12, 2013 04:07 PM — filed under:
“It’s a lifesaver.” That’s how Frances Patterson, a breast cancer patient, describes the therapy she receives for lymphedema through the UNC Comprehensive Cancer Support Program.
Located in News